Get Pep — Free★ 4.7 · Track your GLP-1 doses
Download Scan to download PepScan to get
the app — free
GLP-1 eye risk warning: illustration of an eye beside a medication label

GLP-1 Eye Risk Warning: What the FDA’s NAION Label Means

Home » Blog » GLP-1 Eye Risk Warning: What the FDA’s NAION Label Means

The GLP-1 eye risk warning arrived on November 9, 2026, when the FDA said every GLP-1 medication must add label information about a rare eye condition called NAION. If you take Ozempic, Wegovy, Mounjaro, Zepbound or a GLP-1 pill, the headlines about “sudden blindness” probably landed hard. However, the FDA’s own numbers describe a small possible risk, not a reason to panic. Here is what changed, what the data shows and which symptoms need a same-day call.

What is the FDA’s GLP-1 eye risk warning?

On November 9, 2026, the FDA said it is requiring every GLP-1 receptor agonist to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION), a rare loss of blood flow to the optic nerve that causes sudden, painless vision loss, usually in one eye. In the agency’s review of 126 clinical trials, NAION occurred at 6.4 cases per 100,000 patient-years on a GLP-1 versus 3.8 on a comparator. The FDA calls this a potential increased risk and has not said the drugs cause it. It did not tell people to stop treatment; it told them to report sudden vision changes right away.

Which medications does the GLP-1 eye risk warning cover?

All of them. The FDA’s Drug Safety Communication of November 9, 2026 lists every GLP-1 receptor agonist on the U.S. market, whether it is prescribed for type 2 diabetes or for weight loss:

  • Semaglutide: Ozempic, Wegovy and Rybelsus
  • Tirzepatide: Mounjaro and Zepbound
  • Orforglipron: Foundayo, the daily pill approved in 2026
  • Liraglutide: Victoza and Saxenda
  • Dulaglutide: Trulicity
  • Exenatide, plus the insulin combination products Xultophy and Soliqua

The new text goes in the Warnings and Precautions section of each label. As of November 2026, the FDA’s announcement does not give a date by which the printed labels will change, so the leaflet in your next box may not mention it yet.

What is NAION?

NAION is sometimes described as a small stroke of the optic nerve. According to the FDA, it is caused by decreased blood flow to the front part of the nerve, although the underlying cause is not completely understood. It is uncommon in anyone: published studies put it at roughly 2.3 to 10.2 cases per 100,000 people per year among adults over 50.

The FDA lists these risk factors, which exist with or without a GLP-1:

  • Diabetes
  • High blood pressure
  • Sleep apnea
  • Smoking
  • Anemia
  • Kidney disease

In addition, someone who has already had NAION in one eye has a higher chance of it happening in the other eye. Notice how many of those risk factors overlap with the reasons people are prescribed a GLP-1 in the first place. That overlap is one reason the question has been hard to settle.

How big is the risk? The numbers behind the warning

The FDA looked at several kinds of evidence. Each one points the same direction, and each one is small.

  • Clinical trials. Across 126 randomized trials with 134,253 participants, there were 15 probable NAION cases: 10 among people taking a GLP-1 and 5 among people taking placebo. That works out to 6.4 versus 3.8 cases per 100,000 patient-years. By our arithmetic, that is roughly 2 to 3 additional cases for every 100,000 people treated for a year.
  • Real-world data. In the FDA’s Sentinel database of adults with type 2 diabetes who started treatment between 2019 and 2024, NAION rates were 30 to 32 per 100,000 patient-years on a GLP-1, 31 on an SGLT-2 inhibitor and 26 on a DPP-4 inhibitor. The comparison with SGLT-2 drugs was not statistically significant (hazard ratio 1.19); the comparison with DPP-4 drugs was (hazard ratio 1.43).
  • Earlier studies. The concern began with a July 2024 study in JAMA Ophthalmology that linked semaglutide to NAION. The FDA says it identified several limitations in that study. The European Medicines Agency classified NAION as a very rare side effect of semaglutide in June 2025.

Put together, the FDA describes a “potential increased risk” of a rare event. It also notes that animal studies did not identify a mechanism. In other words, the GLP-1 eye risk warning tells you what to watch for; it does not say the medication will harm your eyes.

Symptoms to act on right away

This is the practical part of the warning. The FDA says to contact a health care professional right away if you notice any of these, particularly in one eye:

  • Sudden, painless loss of vision, which some people first notice on waking
  • Blurred or missing areas of vision, such as a blind spot or tunnel vision
  • Colors that look distorted or washed out
  • A blurry or hazy patch in the center of your sight

Do not wait to see whether it clears, and do not save it for your next routine appointment. The FDA’s instruction to clinicians is to refer suspected NAION promptly to an ophthalmologist. Gradual changes are a different matter: slightly blurry vision as blood sugar improves is common and worth mentioning, but it is not the sudden one-eye change this warning describes.

Should you stop your GLP-1?

The FDA did not tell anyone to stop. For people who have had a NAION event, the agency says to talk with a health care professional about whether to continue or stop, and it tells prescribers to consider discontinuing the medication in those patients unless the benefits clearly outweigh the risk.

For everyone else, this is a conversation rather than an emergency. It is reasonable to raise it at your next visit if you have had NAION before, if you have several of the risk factors above, or if you are due for an eye exam anyway. Stopping on your own has real downsides, which we cover in our guide to what happens when you stop a GLP-1. Also, a weekly GLP-1 does not leave your body the day you stop: semaglutide takes about five weeks to clear, as our Ozempic half-life explainer and the free GLP-1 half-life calculator show.

How tracking helps you have that conversation

An eye doctor who suspects NAION will ask which medication you take, at what dose and since when. Those are easy questions to fumble under stress. Pep is a free GLP-1 tracker app for people on Ozempic, Wegovy, Mounjaro, Zepbound or GLP-1 pills that logs doses, weight, food and side effects. Because every shot or pill is timestamped with its dose, your full history is on your phone when a clinician asks, and the side-effect log keeps a dated record, with severity, of anything you want to raise at your next visit. You can keep that record free with Pep on iPhone and Android.

One caution: an app is for records, not emergencies. Sudden vision loss means calling a clinician first and logging it later. For the common, non-urgent effects, see our guide to managing GLP-1 side effects.

GLP-1 eye risk warning FAQ

Does Ozempic cause blindness?

The FDA has not said that. As of November 2026 it describes a potential increased risk of NAION, a rare condition, and the trial data shows about 6.4 cases per 100,000 patient-years on a GLP-1 versus 3.8 on a comparator. NAION can cause lasting vision loss in the affected eye, which is why sudden changes need immediate attention.

Does the GLP-1 eye risk warning apply to Zepbound and Mounjaro?

Yes. The requirement is class-wide, so it covers tirzepatide (Zepbound and Mounjaro) as well as semaglutide, liraglutide, dulaglutide, exenatide and the Foundayo pill.

Is NAION the same as diabetic retinopathy?

No. Diabetic retinopathy is damage to the blood vessels of the retina that usually develops gradually and is found on routine eye exams. NAION affects the optic nerve and comes on suddenly. They are separate conditions, and the November 2026 GLP-1 eye risk warning is about NAION.

Download Pep free — track your shots, pills & progress in one app.

Download Pep free on the Apple App Store Get Pep free on Google Play

This article is for educational purposes only and is not medical advice. Figures come from the FDA’s Drug Safety Communication of November 9, 2026; talk with your prescriber before changing or stopping any medication, and seek care immediately for sudden vision changes.